FG-3246 Phase 2 dose optimization trial to enroll 75 patients with metastatic castration-resistant prostate cancer (mCRPC) in the post-androgen receptor signaling inhibitor (ASRI) and pre-chemotherapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback